BioCryst Pharma (BCRX) PT Raised to $27 at Citizens on Navenibart Deal, Strong HAE Fit
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $27.00 (from $17.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
